HTG Demonstrates Technical Feasibility for a Whole Transcriptome Panel Using HTG EdgeSeq Technology

TUCSON, Ariz., Nov. 02, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the completion of proof of concept for a whole transcriptome panel using the HTG EdgeSeq technology, and release of a White Paper illustrating the feasibility and performance of this prototype panel relative to RNA sequencing (RNA-Seq). As previously discussed, HTG is developing a whole transcriptome panel utilizing the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned RUO launch in mid-2021.Continue reading

AZBio Issues RFP for a Marketing Consultant to Support the AZAdvances Capital Campaign

Access to early stage growth capital is an ongoing challenge to the growth of Arizona’s Bioindustry. To address this challenge, AZBio, in partnership with the Opportunity Through Entrepreneurship Foundation and with support from a US. Economic Development Agency (EDA) grant has developed AZAdvances.  The Marketing Consultant will work with the AZBio Team to inspire the community and engage support.Continue reading